Ulcerative colitis
Conditions
Interventions
patients who received Infliximab continued to treat every 8 week and who received Adalimumab continued to treat every 2 week. Patients received Tacrolimus 0.5mg2Cap par day at day0. Day0 is day of
Sponsors
Keio University Gastroenterology and Hepatology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients were diagnosed as Ulcerative colitis. 2 pMayo above 2 3 Patients to obtain consent for this study. 4 Over 16years old. 5 Patients received anti TNF-alfa antibody.
Exclusion criteria
Exclusion criteria: 1 Patients with severe Ulcerative colitis. 2 Patients with colitis except for Ulcerative colitis. 3 Patients with gastrointestinal obstruction. 4 Preoperation patients. 5 Patients with severe infection. 6 Patients with severe heart disease. 7 Patients with serum creatinine above 1.2. 8 Patients with serum total Bilirubin above 2.0, AST above 50, ALT above 50. 9 Patients with malignancy or history of malignancy. 10 Patients with neuropsychiatric disorder. 11 women who are or may be pregnant, nursing women and woman who desire to bear children. 12 Inappropriate patients by doctor's judgement. 13 Patients who received a part of other UC therapies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| primary outcome is efficacy at 6 months. Effective is partial Mayo score <3. | — |
Countries
Japan
Contacts
Public ContactMakoto Naganuma
Keio University Gastroenterology and Hepatology
Outcome results
None listed